Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease

INTRODUCTIONIn the era of direct-acting antivirals, hepatitis C virus (HCV) genotype (GT) 3 remains as the most difficult-to-treat HCV-GT. Currently, data on the efficacy of ledipasvir/sofosbuvir plus ribavirin (SOF/LDV+RBV) in GT3-infected patients are limited. We investigated the efficacy of this...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of gastroenterology & hepatology 2018-03, Vol.30 (3), p.291-295
Hauptverfasser:	Moser, Stephan, Kozbial, Karin, Laferl, Hermann, Schütz, Angelika, Reiberger, Thomas, Schwabl, Philipp, Gutic, Enisa, Schwanke, Cornelia, Schubert, Raphael, Luhn, Julian, Lang, Tobias, Schleicher, Michael, Steindl-Munda, Petra, Haltmayer, Hans, Ferenci, Peter, Gschwantler, Michael
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!